KoreaTimes(779) - Bio, Business, page 1

Entertainment
& Arts

Sports

World

SCMP
Asia

Video

Photos

Site Map E-paper Subscribe Register LogIn
Site Map E-paper Subscribe Register LogIn

Business

Bio

Sun, May 29, 2022 | 05:32

[INTERVIEW] Immunomic Therapeutics CEO expects meaningful test results for brain tumor drug

William Hearl, CEO of Immunomic Therapeutics, the U.S. subsidiary of the Korean biotech company, HLB, said that the company expects meaningful test results from its Phase 2 clinical trials of a drug for glioblastoma by August of this year at the latest.

2022-05-26 16:03

HLB gets positive Phase 3 data with liver cancer treatment

HLB has taken a step closer to the global commercialization of its anticancer treatment Rivoceranib as it secured statistical significance in Phase 3 global clinical trials of the drug, according to the local biotech company, Sunday.

2022-05-15 16:23

Lotte seeks to acquire US CMO plant to enter bioindustry

Lotte Group is in the process of acquiring a bioindustry contract manufacturing (CMO) plant in the U.S., according to the investment banking industry, Thursday. The move comes after the conglomerate declared the bioindustry as its new growth engine. CMOs specialize in producing biopharmaceuticals developed by other companies.

2022-05-05 14:46

CHA Biotech's US subsidiary opens CDMO plant in Texas

Matica Biotechnology, a U.S. affiliate of CHA Biotech, has opened a cell and gene therapy manufacturing facility in College Station, Texas, according to the cell therapeutics and stem cell developer affiliate of CHA Medical & Bio Group, Wednesday.

2022-05-04 15:53

Osstem Implant posts record profits for Q1

Osstem Implant posted a record operating profit for the first quarter, the dental equipment manufacturer said Friday.

2022-04-29 16:30

HLB posts earnings surprise in Q1

Local biotech company HLB posted sales and operating profit records for the first quarter. The company announced on April 25 that its quarterly sales rose a whopping 1,052 percent from the same period in 2021 to 63.4 billion won ($50.8 million). Its operating profit also came to 18.8 billion won to turn into a surplus. Both sales and operating profit figures were the highest ...

2022-04-26 15:12

Moon hails Phase 3 trial of SK Bioscience's COVID-19 vaccine

President Moon Jae-in praised a successful Phase 3 trial of the nation's first homegrown COVID-19 vaccine, developed by SK Bioscience, Tuesday.

2022-04-26 15:09

Yoon to visit headquarters of homegrown COVID-19 vaccine

President-elect Yoon Suk-yeol will visit homegrown vaccine producer SK Bioscience on Monday and emphasize vaccine sovereignty amid the country's fight against the novel coronavirus, his spokesperson said.

2022-04-25 10:58

SD Biosensor, Korean COVID-19 test kit maker, to buy Italian firm for 61.9 billion won

SD Biosensor, a Korean developer of COVID-19 test kits, said Friday it has signed a deal to buy an Italian medical device distributor for 61.9 billion won ($49.8 million) in an effort to tap deeper into the European market.

2022-04-22 15:10

SK bioscience to develop antiviral nasal spray

SK bioscience, a biotech affiliate of SK Group, said Wednesday that it will develop a spray-type antiviral drug, with research funds provided by the Bill & Melinda Gates Foundation, a private foundation.

2022-04-14 09:03

1 2 3

CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.